Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/13608
Full metadata record
DC FieldValueLanguage
dc.contributor.authorPatrick, M Ren
dc.contributor.authorChester, K Aen
dc.contributor.authorPietersz, Geoffrey Aen
dc.date.accessioned2015-05-16T03:29:42Z
dc.date.available2015-05-16T03:29:42Z
dc.date.issued1998-06-01en
dc.identifier.citationCancer Immunology, Immunotherapy : Cii; 46(4): 229-37en
dc.identifier.govdoc9671146en
dc.identifier.otherPUBMEDen
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/13608en
dc.description.abstractThe major limitations of monoclonal antibody conjugates as therapeutic agents have been their poor tumour targeting, inadequate tumour penetration and immunogenicity. More even and deeper tissue penetration has been demonstrated with smaller antibody fragments. The smaller size and absence of an Fc segment may contribute to a lowered immunogenicity with single-chain antibodies (scFv) and also permit their recombinant engineering and bacterial expression. We describe the successful engineering, expression and pre-clinical characterisation of a phosphorylatable "kemptide" (Leu-Arg-Arg-Ala-Ser-Gly) anti-carcinoembryonic antigen (anti-CEA) scFv (PKS-scFv), for use as a radioimmunotherapeutic agent. Specifically, a yield of 6 mg/l induced culture was obtained. Site-specific phosphorylation was demonstrated without loss of specificity. In vitro assays revealed a selective cytotoxicity of 32P-PKS-scFv for high-CEA-expressing LS-174T cells compared to the low-CEA-expressing HT-29 cells, with a rapid internalisation rate.en
dc.language.isoenen
dc.subject.otherBinding Sitesen
dc.subject.otherCarcinoembryonic Antigen.chemistry.immunology.metabolismen
dc.subject.otherCloning, Molecularen
dc.subject.otherColonic Neoplasms.metabolism.radiotherapyen
dc.subject.otherDrug Stabilityen
dc.subject.otherEscherichia coli.genetics.metabolismen
dc.subject.otherGenetic Engineering.methodsen
dc.subject.otherHumansen
dc.subject.otherImmunoglobulin Fragments.biosynthesis.chemistry.geneticsen
dc.subject.otherImmunoglobulin Variable Region.biosynthesis.chemistry.geneticsen
dc.subject.otherImmunotoxins.chemistryen
dc.subject.otherOligopeptides.chemistryen
dc.subject.otherPhosphorus Radioisotopes.chemistryen
dc.subject.otherPhosphorylationen
dc.subject.otherRadioimmunotherapyen
dc.subject.otherRecombinant Proteins.biosynthesis.chemistry.geneticsen
dc.subject.otherTumor Cells, Cultureden
dc.titleIn vitro characterization of a recombinant 32P-phosphorylated anti-(carcinoembryonic antigen) single-chain antibody.en
dc.typeJournal Articleen
dc.identifier.journaltitleCancer immunology, immunotherapy : CIIen
dc.identifier.affiliationAustin Research Institute, Austin Hospital, Heidelberg, Victoria, Australiaen
dc.description.pages229-37en
dc.relation.urlhttps://pubmed.ncbi.nlm.nih.gov/9671146en
dc.type.austinJournal Articleen
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.languageiso639-1en-
item.openairetypeJournal Article-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

8
checked on Mar 28, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.